Harvard Bioscience (HBIO) Receivables - Net (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Receivables - Net data on file, last reported at $14.6 million in Q1 2026.

• Quarterly Receivables - Net rose 8.11% year-over-year to $14.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 million (up 8.11% YoY) and the FY2025 annual result came in at $16.0 million, up 7.92% from the prior year.
• Receivables - Net retreated to $14.6 million in Q1 2026 per HBIO's latest filing, from $16.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $20.3 million in Q1 2022 and bottomed at $11.9 million in Q2 2025.
• The 5-year median for Receivables - Net is $15.0 million (2022), against an average of $15.2 million.
• The widest annual swing landed in 2022, when Receivables - Net climbed 18.74%; it then retreated 26.13% in 2024.
• Tracing HBIO's Receivables - Net over 5 years: stood at $16.7 million in 2022, then fell by 3.63% to $16.1 million in 2023, then retreated by 7.66% to $14.9 million in 2024, then climbed by 7.92% to $16.0 million in 2025, then retreated by 9.17% to $14.6 million in 2026.
• Per Business Quant, the three latest HBIO Receivables - Net figures stand at $14.6 million (Q1 2026), $16.0 million (Q4 2025), and $12.1 million (Q3 2025).

Peer Comparison